Proteon Therapeutics Inc (PRTO) Given Consensus Recommendation of “Hold” by Analysts

Proteon Therapeutics Inc (NASDAQ:PRTO) has received an average recommendation of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $2.50.

A number of research firms recently commented on PRTO. JMP Securities downgraded shares of Proteon Therapeutics to a “market perform” rating in a report on Thursday, March 28th. Maxim Group set a $5.00 target price on shares of Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 7th. Zacks Investment Research raised shares of Proteon Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 9th. HC Wainwright lifted their target price on shares of Proteon Therapeutics from $3.00 to $4.00 and gave the stock a “positive” rating in a research report on Monday, March 18th. Finally, Robert W. Baird dropped their target price on shares of Proteon Therapeutics from $3.00 to $1.00 and set a “neutral” rating on the stock in a research report on Friday, March 29th.

Shares of PRTO stock traded down $0.03 during midday trading on Wednesday, reaching $0.55. 59,575 shares of the company were exchanged, compared to its average volume of 1,559,741. Proteon Therapeutics has a 12 month low of $0.45 and a 12 month high of $3.94. The company has a market capitalization of $9.32 million, a price-to-earnings ratio of -0.47 and a beta of 0.64.

Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.01. As a group, sell-side analysts anticipate that Proteon Therapeutics will post -0.98 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. New Leaf Venture Partners L.L.C. grew its position in Proteon Therapeutics by 1.5% during the fourth quarter. New Leaf Venture Partners L.L.C. now owns 1,523,200 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 23,200 shares in the last quarter. Comprehensive Portfolio Management LLC purchased a new position in Proteon Therapeutics during the fourth quarter valued at approximately $68,000. Vanguard Group Inc lifted its stake in Proteon Therapeutics by 45.9% in the third quarter. Vanguard Group Inc now owns 209,383 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 65,833 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Proteon Therapeutics by 45.9% in the third quarter. Vanguard Group Inc. now owns 209,383 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 65,833 shares during the last quarter. 44.87% of the stock is currently owned by institutional investors and hedge funds.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.

Read More: Stock Split

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.